Medannex Ltd’s Post

Breakthrough Treatment: Scientists at King’s College London have developed a tailored drug that targets aggressive breast cancer cells, offering new hope for patients with triple-negative breast cancer. This form of breast cancer is known for its aggressiveness, resistance to chemotherapy, and lower survival rates, affecting mainly women under 40. The treatment combines cetuximab, an antibody that targets the EGFR protein, with a CDK-blocking drug, creating an antibody-drug conjugate that specifically kills breast cancer cells. Promising Results: The research, funded by Breast Cancer Now, has shown potential in minimizing side effects and improving patient outcomes, though more work is needed before clinical use. #ADC #oncology #TNBC

Are we progressing in understanding non-small cell lung cancer (NSCLC)? Clinical Trials Arena recently published an article on the global clinical trials landscape for NSCLC in 2024. NSCLC, which originates from larger cells such as the epithelial cells lining the airways or mucus-producing cells, accounts for about 85% of lung cancer cases worldwide. With around 30% of NSCLC patients diagnosed at an early stage and approximately 70% diagnosed at advanced stages, the need for continued clinical research is paramount. The article highlights that since 2019, the biotech and biopharma industry has initiated over 5,000 NSCLC trials. The Asia-Pacific region led in the number of clinical trials conducted, followed by North America, Europe, and the rest of the world. Ongoing research offers promising opportunities to improve treatment by developing targeted therapies and immunotherapies. Biomarker testing is crucial for patients eligible for these advanced treatments, optimizing treatment choices and improving outcomes, especially in advanced stages. Let’s continue to support and advocate for more research in this area. Together, we can make a difference. #lungcancer #oncology #cancer https://lnkd.in/d9Z8ymbn

#cancerresearch #oncology #cancertreatment https://lnkd.in/ei28tmPq Abstract The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic target in patients with #breast or #gastric #cancer selected on the basis of HER2 overexpression on immunohistochemistry and/or ERBB2 amplification on in situ hybridization. With advances in cancer molecular profiling and increased implementation of precision medicine approaches into oncology practice, actionable HER2 alterations in solid tumours have expanded to include ERBB2 mutations in addition to traditional HER2 overexpression and ERBB2 amplification. These various HER2 alterations can be found in solid tumour types beyond breast and gastric cancer, although few HER2-targeted therapeutic options have been established for the other tumour types. Nevertheless, during the 5 years since our previous Review on this topic was published in this journal, obvious and fruitful progress in the development of HER2-targeted therapies has been made, including new disease indications, innovative drugs with diverse mechanisms of action and novel frameworks for approval by regulatory authorities. These advances have culminated in the recent histology-agnostic approval of the anti-HER2 antibody–drug conjugate trastuzumab deruxtecan for patients with HER2-overexpressing solid tumours. In this new Review, we provide an update on the current development landscape of HER2-targeted therapies beyond breast cancer, as well as anticipated future HER2-directed treatment strategies to overcome resistance and thereby improve efficacy and patient outcomes.

#cancerresearch #oncology #cancertreatment https://lnkd.in/dMxpbStq Study: Breast Cancer Drug Shows Potential for Rare Appendix Cancer.                                                                 Researchers at University of California San Diego School of Medicine found an FDA-approved #drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of #appendix #cancer. The clinical trial results, published in the October 16, 2024 online edition of the Journal of Clinical Oncology, showed the oral medication, known as palbociclib, stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis (PMC). This form of cancer originates in the appendix and is often resistant to standard chemotherapy.

Important Update! New Advancements in the Fight Against Appendix Cancer Using Breast Cancer Drug: Researchers at UC San Diego have found that palbociclib, a breast cancer drug, shows promise for treating a rare form of appendix cancer called peritoneal mucinous carcinomatosis (PMC). Dr. Andrew Lowy, co-senior author and ACPMP Medical Advisory Board Member, says, "Finding that a breast cancer drug is successful in treating a subset of appendix cancer — where treatment options are currently limited — marks a significant advancement in our fight against this disease." This study, funded in part by the Appendix Cancer PMP Research Foundation, offers new hope for patients with this rare form of appendix cancer. Read more: https://lnkd.in/eu2z9Bxa #AppendixCancer #ResearchBreakthrough #HopeForACure #BreastCancer #AppendixCancerResearch UC San Diego Health UC San Diego Health - Moores Cancer Center

Theranostics treatments for cancer is underway at UCLA Health. Offering state-of-the-art facilities and expertise, the 3,000-square-foot Outpatient Theranostics Center in Westwood, part of the UCLA Health Jonsson Comprehensive Cancer Center, specializes in radiopharmaceutical therapy. The center, which opened Feb. 13 & is the largest of its kind in the U.S, is mostly focused on advanced prostate cancer, but it will also treat patients with thyroid cancer and neuroendocrine tumors. Jeremie Calais, MD, PhD, Director of the Ahmanson Translational Theranostics Division of UCLA’s clinical research program anticipates that the rapidly growing field of theranostics could eventually expand to include kidney, breast, lung, pancreatic and liver cancers. Read more here: https://bit.ly/3Z0KqaP . #clinicalresearch #theranostics #cancercare #NationalCancerInstitute #CancerCenters #continuingeducation #UCLA #UCLAHealth

Check out the state of immunotherapy in resectable non-small cell lung cancer (NSCLC): This American Society of Clinical Oncology (ASCO) Educational Book article (free access) includes views from academia and the FDA. Good warmup for #ASCO24 Education Session “Integrating Immunotherapy into Early-Stage Lung Cancer" on June 2. https://lnkd.in/eRiS3Vnx FDA's Dr. Bernardo Haddock Lobo Goulart will present and serve as a panelist in this discussion. → Ongoing trials of immunotherapy and RT for early stage NSCLC. → Clinical implications of recent advances in immunotherapy for resectable NSCLC. → Current trial designs assessing immunotherapy in resectable NSCLC: challenges, opportunities. #LungCancer #Immunotherapy

A newly published article by Helleday laboratory, Karolinska Institute, and Oxcia team suggests that the mitotic MTH1 inhibitor OXC-101 (TH1579) has the potential to enhance the effectiveness of immune checkpoint inhibitors (ICI) in cancer treatment. This is achieved by influencing immune checkpoint-related proteins and pathways. The researchers discovered that treatment with OXC-101 leads to an increase in PD-L1 expression and inflammatory response in cancer cell lines. This finding may provide an explanation for the enhanced effectiveness of the combination of atezolizumab and OXC-101 observed in a syngeneic melanoma disease model. You can read more: https://lnkd.in/dnUD3Pek #oncology #drugdiscovery #Oxcia #OXC101 #mitoticMTH1inhibitor

Scientists from King's College London developed a tailored drug for aggressive breast cancer, specifically targeting triple-negative breast cancer, a challenging form of the disease. ⬇️ - Triple-negative breast cancer is known for its aggressiveness, resistance to chemotherapy, and lower survival rates. - The research team analyzed over 6,000 breast cancer samples to identify properties associated with aggressive and chemotherapy-resistant cancers. - They identified the cancer cell surface marker EGFR and oncogenic molecules CDK critical for cell division and proliferation. ➡️ The researchers combined cetuximab, a tumor-selective antibody targeting EGFR, with a CDK-blocking drug to create a tailored antibody-drug conjugate for patients with this aggressive cancer. The antibody-drug conjugate specifically targets cancer cells, minimizing harm to healthy cells and potentially leading to better patient outcomes. 💡 This approach allows for a lower dose of the inhibitor drug, reducing patients' toxicity while effectively attacking cancer cells. https://lnkd.in/e_MN_y8Y #cancer #cancerresearch #breastcancer #ADC #targetedtherapy

TIL (1 of 7) Exploring Tumor-Infiltrating Lymphocytes (TILs): A New Horizon in Cancer Treatment. TILs represent a groundbreaking approach in cancer immunotherapy, utilizing the body's immune cells that will target and destroy cancer cells. This personalized treatment involves extracting TILs from a patient's tumour, expanding them in a lab, and then reinfusing them into the patient. Despite facing regulatory approval and commercialization challenges, TILs offer a promising future for patients with various cancers. The first disease to show significant results in clinical trials is Melanoma. Illustration: Dall-E AI Read my full blog-post here: https://lnkd.in/grb6mgSJ #TILTherapy #CancerResearch #Immunotherapy #PersonalizedMedicine #OncologyInnovation #Healthcare #MedicalAdvancements #Melanoma